BACE1 适体修饰的四面体型核酸在 APP-PS1 动物模型中治疗阿尔茨海默病。
BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer's Disease in an APP-PS1 Animal Model.
机构信息
Department of Neurosurgery, Sichuan provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
Department of neurosurgery, The First People's Hospital in Shuangliu District/West China Airport Hospital, Sichuan University, Chengdu 610041, China.
出版信息
ACS Appl Mater Interfaces. 2022 Oct 5;14(39):44228-44238. doi: 10.1021/acsami.2c14626. Epub 2022 Sep 23.
Alzheimer's disease is a neurodegenerative disease caused by excessive amyloid β protein-induced neurotoxicity. However, drugs targeting amyloid β protein production face many problems, such as the low utilization rate of drugs by cells and the difficulty of drugs in penetrating the blood-brain barrier. A tetrahedral framework nucleic acid is a new type of nanonucleic acid structure that functions as a therapy and drug carrier. Here, we synthesized a BACE1 aptamer-modified tetrahedral framework nucleic acid and tested its therapeutic effect on Alzheimer's disease and . Our results demonstrated that the tetrahedral framework nucleic acid could be used as a carrier to deliver the BACE1 aptamer to the brain to reduce the production of amyloid β proteins. It also played an antiapoptotic role by reducing the production of reactive oxygen species. Thus, this nanomaterial is a potential drug for Alzheimer's disease.
阿尔茨海默病是一种由过量淀粉样 β 蛋白诱导的神经毒性引起的神经退行性疾病。然而，针对淀粉样 β 蛋白产生的药物面临许多问题，例如药物在细胞中的利用率低以及药物难以穿透血脑屏障。四面体框架核酸是一种新型的纳米核酸结构，可作为治疗和药物载体发挥作用。在这里，我们合成了一种 BACE1 适体修饰的四面体框架核酸，并测试了它对阿尔茨海默病的治疗效果。我们的结果表明，四面体框架核酸可用作载体将 BACE1 适体递送到大脑中以减少淀粉样 β 蛋白的产生。它还通过减少活性氧的产生发挥抗凋亡作用。因此，这种纳米材料是治疗阿尔茨海默病的一种潜在药物。
Zotero 插件